There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback